Physician profile
Usha Agarwal
NPI 1427043421
$2,310.97
in general payments reported to CMS, 2019-2025
21 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $224 · 2021: $373 · 2022: $810 · 2023: $453 · 2024: $146 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $752.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $305.32 | 2020-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $218.19 | 2019-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $192.07 | 2021-2023 | Xarelto, Spravato |
| Novo Nordisk INC | $177.13 | 2022-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $165.91 | 2020-2024 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $158.94 | 2021-2023 | Verquvo, Pifeltro, Dificid |
| Pfizer INC. | $149.66 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $148.33 | 2022-2023 | |
| Gilead Sciences, INC. | $145.98 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.58 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.37 | 2019-2025 | Lifevest |
| Medtronic, INC. | $86.83 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.71 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $59.37 | 2022 | |
| Acist Medical Systems, INC. | $55.97 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $41.63 | 2021-2022 | |
| Dexcom, INC. | $40.12 | 2022-2024 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $38.13 | 2020-2022 | |
| Radius Health, INC. | $20.92 | 2023 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.14 | 2025 | Xifaxan |
| Smith+Nephew, INC. | $11.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usha Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.